Literature DB >> 14742187

Antibody array-generated profiles of cytokine release from THP-1 leukemic monocytes exposed to different amphotericin B formulations.

Lloyd W Turtinen1, David N Prall, Lindsay A Bremer, Rachel E Nauss, Scott C Hartsel.   

Abstract

Cytokine antibody arrays were used to establish the profiles of cytokine release from THP-1 monocytes exposed to different amphotericin B (AMB) drug delivery systems. Fungizone (FZ) and Amphotec (ABCD) caused the release of significantly more inflammatory molecules and the release of inflammatory molecules at higher levels than either AmBisome (L-AMB) or Abelcet (ABLC) after 6 h of treatment. Specifically, tumor necrosis factor alpha (TNF-alpha), interleukin-8 (IL-8), GRO-(alphabetagamma), monocyte chemoattractant protein-1 (MCP-1), RANTES, IL-10, and IL-6 were detected and semiquantified with a chemiluminscence imaging system. TNF-alpha, IL-8, and MCP-1 were the most predominant; however, little if any TNF-alpha was present in ABLC- or L-AMB-treated cultures. The TNF- alpha and IL-8 levels determined by quantitative enzyme-linked immunosorbent assay correlated with the relative cytokine levels measured by using the antibody arrays. Although the viabilities of THP-l monocytes in all AMB-treated cultures were similar by trypan blue exclusion, the amount of lactic dehydrogenase released was significantly larger in FZ- and ABCD-treated cultures than in L-AMB- and ABLC-treated cultures, indicating more membrane perturbations with those formulations. Membrane cation channel formation was also measured in model cholesterol-containing large unilamellar vesicles to directly assess the ion channel formation ability of the system. Only FZ and ABCD induced significant ion currents at concentrations less than 1.5 x 10(-5) M. These results may help provide rationales for the immediate cytokine-mediated side effects observed with FZ and ABCD and the reduced side effects observed with L-AMB and ABLC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14742187      PMCID: PMC321531          DOI: 10.1128/AAC.48.2.396-403.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

1.  Using a CCD camera imaging system as a recording device to quantify human DNA by slot blot hybridization.

Authors:  B Budowle; W R Hudlow; S B Lee; L Klevan
Journal:  Biotechniques       Date:  2001-03       Impact factor: 1.993

2.  Detection of multiple proteins in an antibody-based protein microarray system.

Authors:  R P Huang
Journal:  J Immunol Methods       Date:  2001-09-01       Impact factor: 2.303

3.  Effects of MS-8209, an amphotericin B derivative, on tumor necrosis factor alpha synthesis and human immunodeficiency virus replication in macrophages.

Authors:  P Clayette; M Martin; V Beringue; N Dereuddre-Bosquet; K T Adjou; M Seman; D Dormont
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

Review 4.  Overview of the lipid formulations of amphotericin B.

Authors:  Bertrand Dupont
Journal:  J Antimicrob Chemother       Date:  2002-02       Impact factor: 5.790

5.  The effect of serum albumin on amphotericin B aggregate structure and activity.

Authors:  S C Hartsel; E Bauer; E H Kwong; K M Wasan
Journal:  Pharm Res       Date:  2001-09       Impact factor: 4.200

6.  Differential transcription factor expression in human mononuclear cells in response to amphotericin B: identification with complementary DNA microarray technology.

Authors:  J D Cleary; P D Rogers; S W Chapman
Journal:  Pharmacotherapy       Date:  2001-09       Impact factor: 4.705

Review 7.  Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability.

Authors:  M Tiphine; V Letscher-Bru; R Herbrecht
Journal:  Transpl Infect Dis       Date:  1999-12       Impact factor: 2.228

8.  Potassium-selective amphotericin B channels are predominant in vesicles regardless of sidedness.

Authors:  S C Hartsel; S K Benz; R P Peterson; B S Whyte
Journal:  Biochemistry       Date:  1991-01-08       Impact factor: 3.162

9.  The human homolog of the JE gene encodes a monocyte secretory protein.

Authors:  B J Rollins; P Stier; T Ernst; G G Wong
Journal:  Mol Cell Biol       Date:  1989-11       Impact factor: 4.272

10.  Monocytes may amplify their recruitment into inflammatory lesions by inducing monocyte chemotactic protein.

Authors:  S D Cushing; A M Fogelman
Journal:  Arterioscler Thromb       Date:  1992-01
View more
  6 in total

1.  Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin B.

Authors:  M Simitsopoulou; E Roilides; J Dotis; M Dalakiouridou; F Dudkova; E Andreadou; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

2.  Assessment of effective renal plasma flow, enzymuria, and cytokine release in healthy volunteers receiving a single dose of amphotericin B desoxycholate.

Authors:  Manjunath P Pai; Jeffrey P Norenberg; Robert A Telepak; David S Sidney; Shu Yang
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

3.  Possible impact of salivary influence on cytokine analysis in exhaled breath condensate.

Authors:  T Ichikawa; K Matsunaga; Y Minakata; S Yanagisawa; K Ueshima; K Akamatsu; T Hirano; M Nakanishi; H Sugiura; T Yamagata; M Ichinose
Journal:  Anal Chem Insights       Date:  2007-10-12

4.  It only takes one to do many jobs: Amphotericin B as antifungal and immunomodulatory drug.

Authors:  Ana C Mesa-Arango; Liliana Scorzoni; Oscar Zaragoza
Journal:  Front Microbiol       Date:  2012-08-08       Impact factor: 5.640

5.  Signal stability of Cy3 and Cy5 on antibody microarrays.

Authors:  Qiang Gu; Thamil Mani Sivanandam; Caroline Aehyun Kim
Journal:  Proteome Sci       Date:  2006-10-11       Impact factor: 2.480

6.  Conventional amphotericin B elicits markers of immunogenic cell death on leukemic blasts, mediates immunostimulatory effects on phagocytic cells, and synergizes with PD-L1 blockade.

Authors:  G Kofla; C Radecke; M Frentsch; W Walther; S Stintzing; H Riess; L Bullinger; I-K Na
Journal:  Oncoimmunology       Date:  2022-04-25       Impact factor: 7.723

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.